...
首页> 外文期刊>Gut and Liver >Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)
【24h】

Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)

机译:两个全国范围内的胰腺癌生存预测模型的开发和外部验证:监测,流行病学和最终结果(SEER)和韩国肿瘤登记系统 - 胆道胰腺(KOTUS-BP)

获取原文
           

摘要

Background/Aims: Several prediction models for evaluating the prognosis of nonmetastatic resected pancreatic ductal adenocarcinoma (PDAC) have been developed, and their perfor- mances were reported to be superior to that of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. We developed a prediction model to evaluate the prognosis of resected PDAC and externally validated it with data from a nationwide Korean database. Methods: Data from the Surveillance, Epidemiology and End Results (SEER) database were uti- lized for model development, and data from the Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP) database were used for external validation. Potential candidate variables for model de- velopment were age, sex, histologic differentiation, tumor location, adjuvant chemotherapy, and the AJCC 8th staging system T and N stages. For external validation, the concordance index (C-index) and time-dependent area under the receiver operating characteristic curve (AUC) were evaluated. Results: Between 2004 and 2016, data from 9,624 patients were utilized for model develop- ment, and data from 3,282 patients were used for external validation. In the multivariate Cox proportional hazard model, age, sex, tumor location, T and N stages, histologic differentiation, and adjuvant chemotherapy were independent prognostic factors for resected PDAC. After an exhaustive search and 10-fold cross validation, the best model was finally developed, which included all prognostic variables. The C-index, 1-year, 2-year, 3-year, and 5-year time-dependent AUCs were 0.628, 0.650, 0.665, 0.675, and 0.686, respectively. Conclusions: The survival prediction model for resected PDAC could provide quantitative sur- vival probabilities with reliable performance. External validation studies with other nationwide databases are needed to evaluate the performance of this model.
机译:背景/宗旨:已经开发了几种用于评估非更换切除的胰腺导管腺癌(PDAC)预后的预测模型,据报道,他们的性能优于美国癌症联合委员会(AJCC)的第8版分期系统。我们开发了一种预测模型,以评估切除的PDAC的预后,并用来自全国韩国数据库的数据进行外部验证。方法:来自监测,流行病学和最终结果(SEER)数据库的数据是针对模型开发的,并且来自韩国肿瘤登记系统 - 胆道胰腺(KOTUS-BP)数据库的数据用于外部验证。模型展开的潜在候选变量是年龄,性别,组织学分化,肿瘤位置,佐剂化疗和AJCC第8次分期系统T和N阶段。对于外部验证,评估了接收器操作特征曲线(AUC)下的一致性索引(C折射率)和时间相关区域。结果:2004年至2016年,9,624名患者的数据用于模型开发,3,282名患者的数据用于外部验证。在多变量Cox比例危险模型中,年龄,性别,肿瘤位置,T和N阶段,组织学分化和佐剂化疗是切除PDAC的独立预后因素。在详尽的搜索和10倍交叉验证之后,最终开发了最佳模型,其中包括所有预后变量。 C-Index,1年,2年,3年和5年依赖的AUC分别为0.628,0.650,0.665,0.675和0.686。结论:切除PDAC的生存预测模型可以提供具有可靠性性能的定量概率概率。需要与其他全国范围的数据库进行外部验证研究来评估该模型的性能。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号